PRIME-CKD

Less pills, better pills
Personalized Drug Response:
Implementation and Evaluation in CKD

Read more ›

About Prime-CKD

Chronic Kidney Disease (CKD) is one of the major causes of death in high income countries and its prevalence is growing rapidly. New therapies for the treatment of CKD have shown clear efficacy at a population level. Yet, individual patients respond differently with many patients showing suboptimal efficacy. This indicates that a ‘one size fits all’ approach is no longer sustainable. Currently there are no validated biomarkers (i.e. signal-substances that can be measured in blood or urine) in patients with CKD that aid in guiding optimal therapy for individual patients. Furthermore, there remains a large gap between biomarker research and actual implementation of biomarker based care in daily clinical practice.

“Individual and optimal treatment for every kidney patient; that is what we aim for.”

What is our objective?

The researchproject PRIME-CKD (Personalized drug Response: IMplementation and Evaluation in Chronic Kidney Desease) has a unique advantage to address the challenge we are facing as it builds on recent discoveries of new biomarkers to help guide optimal treatment to individual patients. The research must lead to new therapies for the treatment of CKD.

Read more
Objective of Prime CKD

Latest News

Inclusion of patients for CKD-bioMatch personalized medicine trial started at University Medical Center Hamburg Eppendorf

Read quotes from researchers at the University Medical Center Hamburg Eppendorf about the recruitement of the first CKD-bioMatch patients in Hamburg, Germany. CKD-bioMatch aims to improve treatment for patients with progressive chronic kidney disease (CKD). CKD-bioMatch is now actively recruiting patients across Europe...
Read more

Lund University and Skåne University Hospital recruit first patients for CKD-bioMatch in Sweden

Read quotes from researchers at Lund University and Skåne University Hospital about the recruitement of the first CKD-bioMatch patients in Sweden. This trial aims to improve treatment for patients with progressive chronic kidney disease (CKD). CKD-bioMatch is now actively enrolling patient across Europe...
Read more

CKD-bioMatch trial started at Steno Diabetes Center, Copenhagen

The first patient has enrolled in the CKD-bioMatch trial at Steno Diabetes Center in Copenhagen. CKD-bioMatch is an important part of the PRIME-CKD project. The trial aims to improve treatment for patients with progressive chronic kidney disease (CKD). Read more updates from researchers at Steno Diabetes Center here...
Read more

Prime-CKD news in your mailbox

We can provide you with the latest information via RSS. Click the RSS icon if your browser supports RSS feeds (Chrome or addons).

Or use url https://www.prime-ckd.com/feed in a RSS-reader or an e-mail rss-feed.

Our partners

Copyright © 2024 - Webtail for UMCG Clinical Pharmacy and Pharmacology ]